Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

NCT00196846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2010-06-14

No results posted yet for this study

Summary

Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure

Conditions

Interventions

DRUG

Goserelin

Sponsors & Collaborators

  • GBG Forschungs GmbH

    lead OTHER

Principal Investigators

  • Bernd Gerber, MD · Rostock Universität, Universitätsfrauenklinik

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-12-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196846 on ClinicalTrials.gov